Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) shares rose 3.7% during mid-day trading on Monday . The company traded as high as $135.14 and last traded at $133.42, with a volume of 1,974,691 shares changing hands. The stock had previously closed at $128.60.

ALXN has been the topic of a number of analyst reports. Leerink Swann reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Friday, June 17th. Morgan Stanley raised their price objective on Alexion Pharmaceuticals from $195.00 to $210.00 in a research report on Friday, April 8th. Jefferies Group reissued a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, May 29th. Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $221.00 price objective (down previously from $228.00) on shares of Alexion Pharmaceuticals in a research report on Tuesday, June 7th. Finally, Vetr cut Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $161.67 price objective for the company. in a research report on Monday, April 4th. Seven analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $186.61.

The firm’s 50-day moving average is $124.25 and its 200 day moving average is $140.16. The firm has a market capitalization of $29.92 billion and a PE ratio of 335.43.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.17 by $0.04. The business earned $753 million during the quarter, compared to the consensus estimate of $743.18 million. The business’s revenue was up 18.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.44 earnings per share. Equities research analysts forecast that Alexion Pharmaceuticals Inc. will post $4.71 earnings per share for the current year.

In other Alexion Pharmaceuticals news, EVP John B. Moriarty sold 918 shares of the firm’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $135.72, for a total transaction of $124,590.96. Following the transaction, the executive vice president now owns 51,360 shares of the company’s stock, valued at $6,970,579.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Martin Mackay sold 4,097 shares of the firm’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $139.20, for a total value of $570,302.40. Following the transaction, the executive vice president now directly owns 42,706 shares in the company, valued at approximately $5,944,675.20. The disclosure for this sale can be found here.

Several institutional investors have recently modified their holdings of the company. Bank of Montreal Can raised its position in shares of Alexion Pharmaceuticals by 46.5% in the fourth quarter. Bank of Montreal Can now owns 230,164 shares of the biopharmaceutical company’s stock valued at $43,902,000 after buying an additional 73,039 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Alexion Pharmaceuticals by 7.0% in the fourth quarter. Jennison Associates LLC now owns 7,346,024 shares of the biopharmaceutical company’s stock valued at $1,401,254,000 after buying an additional 481,031 shares during the period. Advantus Capital Management Inc increased its stake in shares of Alexion Pharmaceuticals by 2.7% in the fourth quarter. Advantus Capital Management Inc now owns 21,882 shares of the biopharmaceutical company’s stock valued at $4,174,000 after buying an additional 583 shares during the period. KBC Group increased its stake in shares of Alexion Pharmaceuticals by 46.7% in the third quarter. KBC Group now owns 22,138 shares of the biopharmaceutical company’s stock valued at $3,462,000 after buying an additional 7,045 shares during the period. Finally, Suntrust Banks Inc. increased its stake in shares of Alexion Pharmaceuticals by 131.3% in the fourth quarter. Suntrust Banks Inc. now owns 35,654 shares of the biopharmaceutical company’s stock valued at $6,800,000 after buying an additional 20,240 shares during the period.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.